Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM NEW
-
Total 13F shares
-
5,471,131
-
Share change
-
+1,722,211
-
Total reported value
-
$31,138,734
-
Price per share
-
$5.69
-
Number of holders
-
40
-
Value change
-
+$10,760,012
-
Number of buys
-
29
-
Number of sells
-
14
Institutional Holders of IMPRIMIS PHARMACEUTICALS INC - COM NEW (IMMY) as of Q4 2018
As of 31 Dec 2018,
IMPRIMIS PHARMACEUTICALS INC - COM NEW (IMMY) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,471,131 shares.
The largest 10 holders included
Opaleye Management Inc., Vanguard Group Inc, RENAISSANCE TECHNOLOGIES LLC, EAM Investors, LLC, Diametric Capital, LP, EAM Global Investors LLC, Birchview Capital, LP, ACADIAN ASSET MANAGEMENT LLC, OXFORD ASSET MANAGEMENT LLP, and TWO SIGMA INVESTMENTS, LP.
This page lists
40
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.